Amidst a backdrop of fluctuating consumer sentiment and concerns over elevated valuations in tech stocks, global markets have experienced notable volatility. For investors willing to explore beyond the large-cap landscape, penny stocks—often associated with smaller or newer companies—remain a relevant area of interest. Despite their vintage-sounding name, these stocks can offer surprising value when backed by solid financial foundations, presenting opportunities for those seeking to uncover hidden potential in quality companies.
Top 10 Penny Stocks Globally
| Name | Share Price | Market Cap | Rewards & Risks |
| Lever Style (SEHK:1346) | HK$1.52 | HK$952.52M | ✅ 4 ⚠️ 1 View Analysis > |
| LexinFintech Holdings (NasdaqGS:LX) | $4.15 | $713.44M | ✅ 4 ⚠️ 2 View Analysis > |
| IVE Group (ASX:IGL) | A$3.01 | A$470.29M | ✅ 4 ⚠️ 3 View Analysis > |
| TK Group (Holdings) (SEHK:2283) | HK$2.57 | HK$2.11B | ✅ 4 ⚠️ 1 View Analysis > |
| Angler Gaming (NGM:ANGL) | SEK3.60 | SEK269.95M | ✅ 4 ⚠️ 2 View Analysis > |
| CNMC Goldmine Holdings (Catalist:5TP) | SGD1.09 | SGD441.77M | ✅ 4 ⚠️ 2 View Analysis > |
| Deleum Berhad (KLSE:DELEUM) | MYR1.25 | MYR501.94M | ✅ 4 ⚠️ 1 View Analysis > |
| Yangzijiang Shipbuilding (Holdings) (SGX:BS6) | SGD3.40 | SGD13.38B | ✅ 5 ⚠️ 1 View Analysis > |
| Integrated Diagnostics Holdings (LSE:IDHC) | $0.55 | $319.73M | ✅ 4 ⚠️ 2 View Analysis > |
| DXN Holdings Bhd (KLSE:DXN) | MYR0.52 | MYR2.59B | ✅ 5 ⚠️ 0 View Analysis > |
Click here to see the full list of 3,574 stocks from our Global Penny Stocks screener.
Let's review some notable picks from our screened stocks.
Suning UniversalLtd (SZSE:000718)
Simply Wall St Financial Health Rating: ★★★★★☆
Overview: Suning Universal Co., Ltd is a real estate development company in China with a market cap of CN¥8.19 billion.
Operations: Suning Universal Co., Ltd has not reported any specific revenue segments.
Market Cap: CN¥8.19B
Suning Universal Co., Ltd, a real estate development company in China, has experienced significant financial challenges recently. Despite having short-term assets of CN¥9.7 billion that exceed both its long-term and short-term liabilities, the company remains unprofitable with increased losses over the past five years. Earnings have declined substantially, with a net income drop from CN¥354 million to CN¥100.19 million year-over-year for the nine months ending September 2025. The company's dividend yield is not well-covered by earnings and has been reduced recently, reflecting ongoing financial strain and volatility in its share price amidst broader industry declines.
- Take a closer look at Suning UniversalLtd's potential here in our financial health report.
- Examine Suning UniversalLtd's past performance report to understand how it has performed in prior years.
Xiamen Hexing Packaging Printing (SZSE:002228)
Simply Wall St Financial Health Rating: ★★★★★★
Overview: Xiamen Hexing Packaging Printing Co., Ltd. operates in the packaging and printing industry, providing a range of packaging solutions, with a market cap of CN¥4.35 billion.
Operations: The company's revenue from the packaging manufacturing industry is CN¥10.63 billion.
Market Cap: CN¥4.35B
Xiamen Hexing Packaging Printing Co., Ltd. has faced declining sales, reporting CN¥7.74 billion for the first nine months of 2025, down from CN¥8.59 billion a year earlier, though net income increased to CN¥159.61 million from CN¥144.42 million. Despite a stable dividend yield of 4.41%, it is not well covered by earnings or free cash flow, indicating potential sustainability concerns. The company’s debt levels are manageable with satisfactory coverage by operating cash flow and EBIT, while its seasoned management and board provide stability amidst fluctuating profits and market conditions in the packaging sector.
- Navigate through the intricacies of Xiamen Hexing Packaging Printing with our comprehensive balance sheet health report here.
- Evaluate Xiamen Hexing Packaging Printing's prospects by accessing our earnings growth report.
Tianjin Chase Sun PharmaceuticalLtd (SZSE:300026)
Simply Wall St Financial Health Rating: ★★★★★★
Overview: Tianjin Chase Sun Pharmaceutical Co., Ltd is involved in the research, development, production, and sale of pharmaceutical products both in China and internationally, with a market cap of CN¥11.60 billion.
Operations: Tianjin Chase Sun Pharmaceutical Co., Ltd has not reported any specific revenue segments.
Market Cap: CN¥11.6B
Tianjin Chase Sun Pharmaceutical Co., Ltd has reported declining sales and net income for the first nine months of 2025, with revenue at CN¥4.15 billion compared to CN¥4.44 billion a year ago, and net income dropping to CN¥80.76 million from CN¥168.36 million. Despite this, the company maintains a strong cash position relative to its debt, with short-term assets significantly exceeding both short- and long-term liabilities. Although currently unprofitable with negative return on equity, earnings are forecasted to grow substantially annually, supported by an experienced management team and board of directors providing strategic guidance amidst industry challenges.
- Get an in-depth perspective on Tianjin Chase Sun PharmaceuticalLtd's performance by reading our balance sheet health report here.
- Examine Tianjin Chase Sun PharmaceuticalLtd's earnings growth report to understand how analysts expect it to perform.
Taking Advantage
- Take a closer look at our Global Penny Stocks list of 3,574 companies by clicking here.
- Ready To Venture Into Other Investment Styles? The end of cancer? These 29 emerging AI stocks are developing tech that will allow early idenification of life changing disesaes like cancer and Alzheimer's.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Valuation is complex, but we're here to simplify it.
Discover if Tianjin Chase Sun PharmaceuticalLtd might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com